The dopamine (DA) transporter (DAT) is a membrane protein that regulates dopaminergic neurotransmission by mediating uptake and reverse transport (release) of DA in a Na+-dependent manner. We wish to elucidate the molecular details governing binding and translocation of substances targeting DAT as a first step in the development of therapeutic interventions for diseases involving DAT, such as psychostimulant (cocaine and amphetamine) dependence, neurodegeneration, and psychiatric disorders.
The specific aims i n this proposal are: 1) Characterizing the relationship between DAT activity and the intracellular Na+ level. The hypothesis is that the intracellular Na+ level under depolarizing conditions and thus the action of Na+ channels regulates DAT activity. We will correlate the Na"""""""" level inside cells expressing both DAT and voltage-gated Na+ channel with the ability of DAT to bind and transport DA; and we will probe conformational changes induced by intracellular Na+. 2) Delineating sidedness for action of various substrates at DAT. The hypothesis is that substrates with a modified catechol moiety differ from DA in their ability to access the binding site from the intracellular side of DAT. We will use different DAT preparations, chemical modification, and functional assays to investigate which side of the plasma membrane action of substrates is initiated from; and we will combine structure-activity studies with site-directed mutagenesis to explore, for both substrate and DAT, the structural determinants involved in external and internal access. 3) Assessing functional role of DAT oligomerization. The hypothesis is that oligomeric structures of DAT play a role in asymmetric binding and translocation of substrates, binding of cocaine analogs, conformational changes, and substrate-induced DAT internalization. We will use cells co-expressing two different DAT proteins to determine the minimal function unit for binding and transport, to explore the contribution of inter-monomer interactions to conformational changes of DAT, and to address the relation of oligomerization to the substrate-induced DAT internalization. The planned studies will provide information on the function of DAT in relation to protein structure as well as on the molecular mechanisms of substrate-type psychostimulants or parkinsonism-inducing toxins, and may lead to identification of asymmetrically-acting substrates that could be tools for DAT studies. Results may also help understanding the closely related serotonin and norepinephrine transporters that are linked to mental illness. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA019676-02
Application #
7286036
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Koustova, Elena
Project Start
2006-09-15
Project End
2010-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
2
Fiscal Year
2007
Total Cost
$284,933
Indirect Cost
Name
New York University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Zhen, Juan; Reith, Maarten E A (2018) Functional properties of dopamine transporter oligomers after copper linking. J Neurochem 144:162-171
Jones, Kymry T; Woods, Catherine; Zhen, Juan et al. (2017) Effects of diet and insulin on dopamine transporter activity and expression in rat caudate-putamen, nucleus accumbens, and midbrain. J Neurochem 140:728-740
Reith, Maarten E A; Jones, Kymry T; Zhen, Juan et al. (2017) Latch and trigger role for R445 in DAT transport explains molecular basis of DTDS. Bioorg Med Chem Lett :
Challasivakanaka, Sathya; Zhen, Juan; Smith, Margaret E et al. (2017) Dopamine transporter phosphorylation site threonine 53 is stimulated by amphetamines and regulates dopamine transport, efflux, and cocaine analog binding. J Biol Chem 292:19066-19075
Karpowich, Nathan K; Song, Jinmei; Wang, Da-Neng (2016) An Aromatic Cap Seals the Substrate Binding Site in an ECF-Type S Subunit for Riboflavin. J Mol Biol 428:3118-30
Zhen, Juan; Reith, Maarten E A (2016) Impact of disruption of secondary binding site S2 on dopamine transporter function. J Neurochem 138:694-9
Sauer, David B; Karpowich, Nathan K; Song, Jin Mei et al. (2015) Rapid Bioinformatic Identification of Thermostabilizing Mutations. Biophys J 109:1420-8
Zhen, Juan; Antonio, Tamara; Cheng, Shu-Yuan et al. (2015) Dopamine transporter oligomerization: impact of combining protomers with differential cocaine analog binding affinities. J Neurochem 133:167-73
Reith, Maarten E A; Blough, Bruce E; Hong, Weimin C et al. (2015) Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend 147:1-19
Stödberg, Tommy; McTague, Amy; Ruiz, Arnaud J et al. (2015) Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures. Nat Commun 6:8038

Showing the most recent 10 out of 32 publications